Financial Data and Key Metrics Changes - Total revenue for the second quarter of 2025 was $19,600,000, an 8% decrease compared to the same period in the prior year [19] - Surgical glaucoma revenue was $19,200,000, a decrease of 5%, primarily due to an 11% decrease in account utilization [19] - Dry eye revenue was $300,000, down from $1,100,000 in 2024, attributed to fewer SmartLid sales [19] - Gross margin was 85%, down from 86%, with surgical glaucoma gross margin at 86% compared to 88% [20] - Net loss was $11,900,000 or $0.23 per share, compared to a net loss of $12,300,000 or $0.25 per share in the prior year [21] Business Line Data and Key Metrics Changes - Surgical glaucoma segment showed a sequential growth in ordering accounts, up 6% sequentially and 4% year-over-year [11] - Surgical glaucoma utilization increased by 4% sequentially, contributing to strong quarterly performance [11] - Dry eye segment revenue decreased significantly due to a focus on achieving reimbursed market access for tear care procedures [13][20] Market Data and Key Metrics Changes - The company is experiencing a stable market environment despite headwinds from Medicare coverage restrictions [32] - The demand for minimally invasive glaucoma treatments is expected to grow, representing a significant long-term market opportunity [8] Company Strategy and Development Direction - The company is focused on securing equitable reimbursement for tier care and driving commercial momentum in MIGS through the rollout of OmniEdge [18] - Strategic initiatives include enhancing competitive positioning, investing in commercial resources, and expanding the pseudophakic standalone omni market [10] - The company aims to build on early traction with OmniEdge and improve surgeon education on standalone procedures [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive adoption of the Omni procedure, citing a shift in surgeon mindset towards interventional glaucoma [9] - The company remains optimistic about achieving reimbursement coverage for tier care, despite delays [38][40] - Future growth is anticipated in the surgical glaucoma segment, with expectations of mid-single-digit declines in the near term [25] Other Important Information - The company has not yet received monetary damages from a patent infringement case against Alcon, and ongoing legal proceedings may impact future revenue [23][24] - The company is exploring additional third-party manufacturing locations to enhance production capabilities starting in 2026 [26] Q&A Session Summary Question: What is driving the strength in the surgical glaucoma business? - Management noted stability in the market and effective execution by the sales team, contributing to better-than-expected performance [32][34] Question: When can reimbursement wins for tier care be expected? - Management indicated that while they are working towards reimbursement wins in 2025, the timing is uncertain [38][40] Question: How is the competitive landscape evolving? - Management acknowledged ongoing competition but emphasized their strong performance and market position, particularly with the Omni product line [46][48] Question: What is the outlook for the second half of the year? - Management expects a mid-single-digit decline in surgical glaucoma revenue for Q3, with potential for growth in Q4 as they lap previous restrictions [52][53] Question: What are the obstacles to standalone MIGS adoption? - Management highlighted the need for a prescriptive approach to identify and treat specific patient populations, emphasizing the importance of education and workflow integration [92][96]

Financial Performance - Hayward's Q2 2025 net sales reached $299.6 million, a 5% increase year-over-year[11] - The company achieved a record gross profit margin of 52.7% in Q2 2025, up 170 bps year-over-year[8, 11] - Adjusted EBITDA for Q2 2025 was $88.2 million, a 7% increase year-over-year, with an adjusted EBITDA margin of 29.5%, up 50 bps[11] - Adjusted diluted EPS increased by 14% year-over-year to $0.24[11, 19] Segment Performance - North America net sales were $255.2 million, a 5.8% increase year-over-year, with a gross profit margin of 55.1%[22] - Europe & Rest of World net sales were $44.4 million, a 2.7% increase year-over-year, with a gross profit margin of 38.9%[23] Financial Position and Outlook - Net leverage was reduced to 2.1x, the lowest level since Q1 2022[8, 25] - The company has refined its full-year 2025 guidance, raising the lower end of the net sales range to between $1.070 billion and $1.100 billion[8, 35] - Full year free cash flow is expected to be approximately $150 million[35] Tariff Mitigation - The company is mitigating tariff impacts by reducing China direct sourcing into the US from approximately 10% to approximately 3% of COGS by the end of 2025[17] - A 3% price increase was implemented in North America in April as part of tariff mitigation efforts[17]

Financial Data and Key Metrics Changes - Organic growth for Q2 2025 was 3%, aligning with expectations, while non-GAAP adjusted EBITDA margin remained flat at 15.3% compared to the previous year [5][20]. - Non-GAAP adjusted net income per share increased by 5.1% to $2.50, compared to the same period in 2024 [6][32]. - Cash flow supported dividends, acquisitions, and share repurchases, with $223 million used for share repurchases in the first half of 2025, on track for a total of $600 million for the year [6][35]. Business Line Data and Key Metrics Changes - Media and advertising grew by 8%, driven by strong media performance, while precision marketing increased by 5% [24]. - Public relations saw a decline of 9%, primarily in the U.S., due to weaker performance in global networks [25]. - Healthcare revenues decreased by 5%, and branding and retail commerce fell by 17% due to market uncertainties [26][27]. Market Data and Key Metrics Changes - The U.S. market experienced organic growth of 3%, while Asia Pacific and Continental Europe also posted solid growth, with the UK being the only region without growth [28]. - The auto category saw year-over-year increases, reflecting new business wins, although some client spend reductions were noted [28]. Company Strategy and Development Direction - The company is focused on completing the acquisition of Interpublic, with 13 out of 18 required jurisdictions approved, aiming for a seamless integration [7][10]. - A reorganization of advanced data and technology assets into a platform organization was implemented to enhance client service and accelerate growth [10][11]. - The strategy emphasizes the integration of generative AI to enhance creativity and operational efficiency, positioning the company for long-term competitive advantage [14][18]. Management's Comments on Operating Environment and Future Outlook - Management noted that while macroeconomic uncertainties persist, they remain confident in achieving full-year organic growth and margin targets [13][20]. - The company is prepared to adapt to changing market conditions and is optimistic about future growth opportunities, particularly post-acquisition [70][71]. Other Important Information - The company has appointed a new Chief People Officer to enhance HR capabilities and attract top talent [12]. - The integration planning for Interpublic is ongoing, with a focus on achieving identified synergies [13][76]. Q&A Session Summary Question: Can you speak to the progression of things since your last update in April? - Management indicated that the environment has not changed significantly, with ongoing macro concerns being manageable [40][41]. Question: How do you view the sustainability and growth of principal trading? - Management expressed confidence in the continued growth of media, highlighting their unique product offerings [46][47]. Question: What is the expected impact of AI agents on financials? - The deployment of AI agents is expected to enhance operational efficiency and drive top-line growth, although the full financial impact is yet to be determined [60][62]. Question: How do you view the current pipeline of opportunities? - Management noted that while some decision processes have slowed, they continue to be invited to significant pitches, indicating ongoing interest from clients [88][89]. Question: How should repositioning and acquisition-related costs be modeled for the year? - Management clarified that repositioning costs are separate from the synergy target and do not expect further charges in the near term [82][83]. Question: How does the company view the impact of new AI tools on the creative business model? - Management believes that advancements in AI will enhance creativity and efficiency, allowing for new compensation models based on outcomes rather than time spent [106][111].

Core Insights - Glaukos Corporation (GKOS) reported a record-breaking first-quarter 2025 performance with revenues of $106.7 million, a 25% year-over-year increase, primarily driven by the adoption of the iDose TR implant [1][8] - The company reaffirmed its full-year revenue guidance of $475-$485 million, indicating confidence in its commercial momentum [1] Near-Term Growth Drivers - The iDose TR launch is gaining traction, with U.S. glaucoma sales increasing by 41% year-over-year, contributing nearly $21 million in the first quarter, reflecting an $85 million annualized run rate [3] - Internationally, Glaukos achieved $29 million in interventional glaucoma sales, a 15% year-over-year increase, supported by the growing acceptance of minimally invasive glaucoma surgery (MIGS) [4] Long-Term Growth Catalysts - Glaukos has a robust R&D pipeline with key programs including Epioxa, iDose Trex, PRESERFLO MicroShunt, and GLK-401, which are expected to broaden the company's addressable market in the next three to five years [5][6] - The company is cultivating standalone use of MIGS devices like iStent infinite, anticipating long-term growth as more surgeons adopt interventional glaucoma practices [7] Challenges and Watchpoints - Reimbursement complexities and LCD restrictions are impacting legacy stent sales, which declined mid-single digits in the first quarter, with expectations of continued pressure through 2025 [8][9] - Sales of Photrexa remain muted due to the Medicaid Drug Rebate Program, with near-term growth in this segment expected to be flat to low-single digits [10] Competitive Landscape - The iDose TR launch positions Glaukos ahead in procedural glaucoma drug delivery, but competition from Alcon, Johnson & Johnson, and Sight Sciences remains significant [11] - Year-to-date, Glaukos shares have declined by 31.7%, underperforming its rivals in the MIGS space, while Alcon and J&J have seen increases [12]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $17,500,000, reflecting a 9% decrease compared to the same period in the prior year [19][21] - Surgical glaucoma revenue was $17,100,000, a decrease of 6% year-over-year, primarily due to a 10% decrease in account utilization [20][21] - Dry eye revenue was $400,000, down from $1,000,000 in the same period last year, attributed to fewer SmartLids sales following a price increase [21][16] - Gross margin for the first quarter was 86%, unchanged from the prior year [21] - Net loss for the quarter was $14,200,000, or $0.28 per share, compared to a net loss of $16,300,000, or $0.33 per share, in the prior year [22] Business Line Data and Key Metrics Changes - Surgical glaucoma segment showed a slight decline in sequential ordering accounts, with a 3% increase year-over-year despite new Medicare restrictions [20][10] - The dry eye segment's revenue reflects ongoing efforts in market access and new pricing strategies [16][21] Market Data and Key Metrics Changes - The MIGS market is experiencing changes due to new Medicare coverage restrictions, limiting the number of MIGS procedures performed during cataract surgery [9][10] - The company is actively engaging with surgeons to adapt to the new environment and optimize commercial strategies [10][31] Company Strategy and Development Direction - The company is focused on addressing unmet medical needs in glaucoma and dry eye markets through innovative interventional technologies [7][15] - Strategic initiatives include building commercial momentum in MIGS, establishing equitable reimbursement for tier care, and advancing the product pipeline [7][15] - Plans to expand manufacturing operations outside of China to mitigate tariff impacts are underway [8][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for glaucoma treatments and the company's ability to adapt to the new MIGS environment [10][9] - The company reaffirmed its revenue guidance for 2025, expecting total revenue of approximately $70,000,000 to $75,000,000 [23][24] - Management highlighted the importance of ongoing conversations with payers regarding reimbursement for tier care procedures [45][46] Other Important Information - The company has not yet received any monetary damages from a patent infringement case against Alcon, awaiting final rulings [22] - Adjusted operating expenses for the first quarter were $24,700,000, a decrease of 7% compared to the prior year [22][26] Q&A Session Summary Question: Can you discuss trends in surgical glaucoma and share dynamics? - Management noted a decline in actual utilization but emphasized the continued growth in patient encounters and the effectiveness of the Omni product [30][31] Question: Are there efforts to reverse the stacking component of the LCDs? - Management acknowledged multiple efforts to collect clinical data supporting the need for multiple MIGS procedures [36] Question: What are the reimbursement dynamics for Omni versus competitive MIGS devices? - The reimbursement dynamics remain largely unchanged, with most procedures historically performed as single MIGS [43] Question: Any updates on tier care reimbursement? - No coverage determinations have been made yet, but management is optimistic about future decisions [45][46] Question: Can you provide insights on the Scion product? - Scion is a complementary product with modest revenue contribution, primarily serving surgeons looking for simpler procedures [49][50] Question: What is the outlook for device intensive qualification? - Management expressed strong conviction that the device should qualify for device intensive but refrained from speculation [58] Question: How is the company addressing competitive launches? - Management remains confident in Omni's market position and is actively monitoring competitive dynamics [88]

Financial Data and Key Metrics Changes - Total revenue for the first quarter of 2025 was $17.5 million, reflecting a 9% decrease compared to the same period in the prior year [20] - Surgical glaucoma revenue was $17.1 million, a decrease of 6% year-over-year, primarily due to a 10% decline in account utilization [20] - Dry eye revenue was $400,000, down from $1 million in the same period last year, attributed to fewer SmartLids sales following a price increase [21] - Gross margin for the first quarter was 86%, unchanged from the prior year [21] - Net loss for the quarter was $14.2 million, or $0.28 per share, compared to a net loss of $16.3 million, or $0.33 per share, in the first quarter of 2024 [22] Business Line Data and Key Metrics Changes - Surgical glaucoma segment showed a revenue of $17.1 million, with a slight decline in sequential ordering accounts despite new Medicare restrictions [11][20] - Dry eye segment revenue was $400,000, reflecting a focus on market access and new pricing strategies [17][21] Market Data and Key Metrics Changes - The MIGS market is experiencing changes due to new Medicare coverage restrictions, limiting the number of MIGS procedures performed during cataract surgery [10][20] - The company is actively working to establish third-party manufacturing lines outside of China to mitigate tariff impacts [9][25] Company Strategy and Development Direction - The company aims to build commercial momentum in the MIGS market through customer education, equitable reimbursement, and new clinical data [8][16] - Focus on advancing the product pipeline, including the recent launch of the next-generation OmniEdge [13][15] - The long-term strategy includes pioneering interventional procedures for moderate to severe meibomian gland disease (MGD) in the dry eye market [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for glaucoma treatment and the ability to adapt to the new MIGS environment [11][20] - The company reaffirmed its revenue guidance for 2025, expecting total revenue of approximately $70 million to $75 million [23][24] - Management is optimistic about the potential for reimbursement coverage decisions for tier care procedures in 2025 [44][68] Other Important Information - The company is awaiting a final ruling on a patent infringement case against Alcon, which could impact future financials [22] - Adjusted operating expenses for 2025 are expected to be between $101 million and $105 million, reflecting a focus on fiscal discipline [26] Q&A Session Summary Question: Trends in surgical glaucoma and share dynamics - Management noted a decline in actual utilization due to new Medicare restrictions but emphasized the continued reliance on the Omni product for its comprehensive efficacy [30][31] Question: Efforts to reverse the stacking component of LCDs and competition - Management acknowledged ongoing efforts to collect clinical data supporting multiple MIGS procedures and discussed competitive dynamics in the MIGS market [34][35][39] Question: Reimbursement mechanics for Omni versus competitors - Management indicated that reimbursement dynamics remain largely unchanged, with the majority of procedures still performed as single MIGS [42] Question: Update on tier care reimbursement - Management confirmed no coverage determinations have been made yet but expressed optimism about ongoing discussions with payers [44][45][68] Question: Scion product performance and revenue contribution - Management stated that Scion is a modest portion of total revenue, primarily serving as a complementary product to Omni [48][49] Question: Tariff impact and mitigation strategies - Management expects minor impacts to gross margin in 2026 as new manufacturing locations are phased in [52][53] Question: Outlook for device intensive qualification - Management refrained from speculating on device intensive qualification but expressed strong conviction that the device should qualify based on procedure costs [57] Question: Revenue cadence and pricing strategy - Management expects sequential revenue growth in the second quarter, with a typical seasonal pattern throughout the year [60][80]

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was $19.1 million, reflecting a 2% increase compared to the same period in the prior year [10][36] - Surgical glaucoma revenue for Q4 2024 was $18.8 million, up 9% year-over-year, driven by a 7% increase in ordering accounts and a 6% increase in account utilization [37][16] - Dry eye revenue for Q4 2024 was $0.3 million, a decrease from $1.6 million in the same period last year, primarily due to fewer SmartLid sales [38][36] - Gross margin for Q4 was 87%, an increase from 85% in the prior year, mainly due to an improved surgical glaucoma product mix [39] - The net loss for Q4 was $11.8 million, or $0.23 per share, compared to a net loss of $10.7 million, or $0.22 per share for Q4 2023 [39] Business Line Data and Key Metrics Changes - Surgical glaucoma revenue grew 9% year-over-year, despite headwinds from new Medicare LCDs [16][37] - The number of customers ordering surgical glaucoma products increased by 3% sequentially and 7% year-over-year [38] - The dry eye segment is focused on achieving reimbursed market access, with a significant decline in revenue due to strategic shifts [36][25] Market Data and Key Metrics Changes - The MIGS market has faced challenges due to new Medicare LCDs, impacting the ability to bill for multiple MIGS procedures [17][19] - Despite short-term declines in MIGS utilization, the company anticipates long-term growth driven by increasing patient demand for glaucoma treatment [19][42] - The company estimates over 13 million U.S. patients are diagnosed with Meibomian gland disease, indicating a significant market opportunity for TearCare [25] Company Strategy and Development Direction - The company aims to build commercial momentum in MIGS and establish equitable reimbursement for TearCare, focusing on customer education and engagement [13][34] - Plans for 2025 include launching the next-generation Omni Edge and continuing to develop the Pseudophakic standalone market [21][45] - The company is committed to addressing the unmet needs in glaucoma and dry eye markets through innovative interventional technologies [11][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow break-even without raising additional equity capital [35] - The company expects 2025 to be transformational, anticipating positive coverage decisions for TearCare [14][41] - Management acknowledged the impact of tariffs on gross margins and operational results, while planning to mitigate these costs through various adjustments [44][45] Other Important Information - The company ended Q4 with $120.4 million in cash and cash equivalents and $40 million in debt [40] - The company has not yet received monetary damages from a patent infringement case against Alcon, with the final ruling pending [41] Q&A Session Summary Question: How is market development on the standalone MIGS market going? - Management noted good momentum in capturing broader adoption of interventional mindset in glaucoma care, with ongoing education efforts [48][51] Question: Can you provide updates on TearCare reimbursement claims? - Management reported increasing volume of claims with some early traction from specific payers, but standardization is still lacking [58][61] Question: What are the trends in surgical glaucoma since the new LCDs? - Management indicated that trends are tracking as expected, with good engagement from customers on where OMNI fits into treatment paradigms [66][70] Question: How is the competitive landscape affecting OMNI volumes? - Management expressed confidence in OMNI's strong market position despite new entrants, emphasizing the importance of clinical evidence and usability [115][117]